![Fouzia Laghrissi-Thodes](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fouzia Laghrissi-Thodes
Director/Board Member at
MINERVA NEUROSCIENCES, INC.
Net worth: - $ as of 30/09/2026
Profile
Dr. Fouzia Laghrissi-Thodes, MD, is a Chief Executive Officer & Director at DalCor Pharmaceuticals Canada, Inc., an Independent Director at Minerva Neurosciences, Inc. and an Independent Director at Smart Immune SAS. She is on the Board of Directors at DalCor Pharmaceuticals Canada, Inc., Minerva Neurosciences, Inc., Cellaïon SA and Smart Immune SAS. Dr. Laghrissi-Thodes was previously employed as a VP-Cardiovascular & Metabolism Therapy by AstraZeneca PLC and a Chief Executive Officer by ZS Pharma, Inc. She also served on the board at Nuro Corp.
She received her doctorate degree from Université François-Rabelais de Tours.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 03/06/2026 | 0 ( -.--% ) | - $ | 30/09/2026 |
Fouzia Laghrissi-Thodes active positions
| Companies | Position | Start |
|---|---|---|
| MINERVA NEUROSCIENCES, INC. | Director/Board Member | 18/05/2015 |
DalCor Pharmaceuticals Canada, Inc.
 DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Develops precision treatments for cardiovascular disease | Chief Executive Officer | 03/04/2018 |
Smart Immune SAS
 Smart Immune SAS BiotechnologyHealth Technology Develops T-cell progenitor-based cell and gene therapy | Director/Board Member | - |
Promethera Therapeutics SA
 Promethera Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops novel therapies | Director/Board Member | - |
Former positions of Fouzia Laghrissi-Thodes
| Companies | Position | End |
|---|---|---|
| ZS PHARMA INC | Chief Executive Officer | - |
Nuro Corp.
 Nuro Corp. Packaged SoftwareTechnology Services Develops neurological communication software solutions | Director/Board Member | - |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Education of Fouzia Laghrissi-Thodes
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
42
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
ZS Pharma, Inc.
 ZS Pharma, Inc. BiotechnologyHealth Technology Develops develop new treatments of kidney and liver diseases | Health Technology |
Université François-Rabelais de Tours
 Université François-Rabelais de Tours Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Minerva Neurosciences, Inc.
 Minerva Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes drugs to treat patients suffering from central nervous system diseases | Health Technology |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Develops precision treatments for cardiovascular disease | Health Technology |
Nuro Corp.
Nuro Corp. Packaged SoftwareTechnology Services Develops neurological communication software solutions | Technology Services |
Smart Immune SAS
Smart Immune SAS BiotechnologyHealth Technology Develops T-cell progenitor-based cell and gene therapy | Health Technology |
Promethera Therapeutics SA
Promethera Therapeutics SA Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops novel therapies | Commercial Services |
- Stock Market
- Insiders
- Fouzia Laghrissi-Thodes
